Raymond Dingledine Selected Research

Encephalitis (Encephalitis, Rasmussen)

3/2024	MyD88-mediated signaling is critical for the generation of seizure responses and cognitive impairment in a model of anti-N-methyl-D-aspartate receptor encephalitis.
1/2021	Monoclonal Antibodies From Anti-NMDA Receptor Encephalitis Patient as a Tool to Study Autoimmune Seizures.
1/2021	Seizures and memory impairment induced by patient-derived anti-N-methyl-D-aspartate receptor antibodies in mice are attenuated by anakinra, an interleukin-1 receptor antagonist.
1/2019	A mouse model of seizures in anti-N-methyl-d-aspartate receptor encephalitis.
3/2018	Beneficial Outcome of Urethane Treatment Following Status Epilepticus in a Rat Organophosphorus Toxicity Model.
6/2015	Inhibition of the prostaglandin EP2 receptor is neuroprotective and accelerates functional recovery in a rat model of organophosphorus induced status epilepticus.
4/2015	Therapeutic window for cyclooxygenase-2 related anti-inflammatory therapy after status epilepticus.
2/2013	Inhibition of the prostaglandin receptor EP2 following status epilepticus reduces delayed mortality and brain inflammation.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Raymond Dingledine Research Topics

Disease

22	Seizures (Absence Seizure) 03/2024 - 06/2002
22	Status Epilepticus (Complex Partial Status Epilepticus) 12/2023 - 07/2003
13	Epilepsy (Aura) 12/2023 - 06/2002
10	Neuroinflammatory Diseases 01/2023 - 08/2012
9	Inflammation (Inflammations) 01/2021 - 10/2007
8	Encephalitis (Encephalitis, Rasmussen) 03/2024 - 02/2013
6	Gliosis 02/2022 - 06/2015
4	Anti-N-Methyl-D-Aspartate Receptor Encephalitis 03/2024 - 01/2019
3	Alzheimer Disease (Alzheimer's Disease) 11/2021 - 05/2015
3	Weight Loss (Weight Reduction) 03/2018 - 02/2013
2	Memory Disorders (Memory Loss) 03/2024 - 01/2019
2	Infections 01/2015 - 10/2007
2	Neurodegenerative Diseases (Neurodegenerative Disease) 01/2014 - 10/2007
2	Temporal Lobe Epilepsy 08/2012 - 07/2003
2	Parkinson Disease (Parkinson's Disease) 06/2010 - 02/2005
2	Neoplasms (Cancer) 07/2008 - 10/2007
1	Disease Progression 12/2023
1	Poisoning 01/2021
1	Dyskinesias (Dyskinesia) 01/2021
1	Cognitive Dysfunction 01/2021
1	Nervous System Diseases (Neurological Disorders) 01/2019
1	Cardiotoxicity 01/2019
1	Autoimmune Diseases of the Nervous System 01/2019
1	Partial Epilepsies (Epilepsy, Partial) 01/2018

Drug/Important Bio-Agent (IBA)

11	Pilocarpine (Ocusert)FDA LinkGeneric 02/2022 - 07/2003
8	Dinoprostone (PGE2)FDA Link 01/2021 - 02/2012
6	Isoflurophate (DFP)FDA Link 01/2021 - 06/2015
5	AntibodiesIBA 03/2024 - 01/2018
5	ProstaglandinsIBA 11/2021 - 10/2014
5	Anticonvulsants (Antiepileptic Drugs)IBA 01/2015 - 06/2002
4	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 03/2024 - 01/2019
4	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 01/2023 - 02/2013
4	Messenger RNA (mRNA)IBA 01/2021 - 05/2007
4	TG6-10-1IBA 01/2020 - 02/2013
2	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 03/2024 - 01/2021
2	Proteins (Proteins, Gene)FDA Link 03/2024 - 05/2015
2	CalciumIBA 03/2024 - 01/2017
2	OrganophosphatesIBA 01/2022 - 01/2020
2	CytokinesIBA 01/2021 - 06/2015
2	InterleukinsIBA 01/2021 - 01/2014
2	SomanIBA 01/2021 - 11/2016
2	Immunoglobulin G (IgG)IBA 01/2021 - 01/2019
2	Urethane (Ethyl Carbamate)IBA 01/2020 - 03/2018
2	AlbuminsIBA 01/2019 - 01/2018
2	Cyclooxygenase 2 Inhibitors (COX-2 Inhibitors)IBA 01/2019 - 01/2014
2	Transcription Factors (Transcription Factor)IBA 01/2019 - 12/2012
2	BenzodiazepinesIBA 03/2018 - 01/2015
2	RNA (Ribonucleic Acid)IBA 01/2017 - 06/2010
2	Kainic Acid (Kainate)IBA 01/2017 - 10/2014
2	Cholinergic Agents (Cholinergics)IBA 01/2017 - 06/2015
1	Glial Fibrillary Acidic ProteinIBA 03/2024
1	Toll-Like Receptors (Toll-Like Receptor)IBA 03/2024
1	tofacitinibIBA 12/2023
1	Histone MethyltransferasesIBA 12/2023
1	Janus Kinase 1IBA 12/2023
1	Cholinesterases (Cholinesterase)IBA 01/2022
1	Nerve AgentsIBA 01/2021
1	Monoclonal AntibodiesIBA 01/2021
1	Interleukin-1 (Interleukin 1)IBA 01/2021
1	LigandsIBA 01/2021
1	N-Methylaspartate (NMDA)IBA 01/2021
1	CC ChemokinesIBA 01/2021
1	G-Protein-Coupled Receptors (Receptors, G Protein Coupled)IBA 01/2021
1	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 01/2021
1	fluorophosphate (sodium monofluorophosphate)FDA Link 01/2020
1	LeukotrienesIBA 01/2019
1	Prostaglandin D2IBA 01/2019
1	Enhancer of Zeste Homolog 2 ProteinIBA 01/2019
1	LipoxinsIBA 01/2019
1	EndocannabinoidsIBA 01/2019
1	Immunoglobulins (Immunoglobulin)IBA 01/2019
1	Amyloid (Amyloid Fibrils)IBA 01/2019
1	Peptides (Polypeptides)IBA 01/2019
1	AutoantibodiesIBA 01/2019
1	Diazepam (Valium)FDA LinkGeneric 03/2018
1	Biomarkers (Surrogate Marker)IBA 01/2018
1	Adenosine (Adenocard)FDA LinkGeneric 01/2018
1	Losartan (Cozaar)FDA LinkGeneric 01/2018
1	HMGB1 Protein (HMG1)IBA 01/2018
1	Isoflurane FDA LinkGeneric 01/2018
1	Carbachol (Carbastat)FDA Link 01/2017
1	Ammonium CompoundsIBA 01/2017
1	BromidesIBA 01/2017
1	Atropine FDA LinkGeneric 01/2017
1	Organophosphorus CompoundsIBA 06/2015
1	FructoseIBA 05/2015
1	Advanced Glycation End ProductsIBA 05/2015
1	Kainic Acid Receptors (Kainate Receptor)IBA 10/2014
1	Protein Kinase CIBA 10/2014
1	ChemokinesIBA 01/2014
1	EnzymesIBA 01/2014
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2014
1	Prostaglandin Receptors (Prostaglandin Receptor)IBA 02/2013
1	RE1-silencing transcription factorIBA 12/2012

Therapy/Procedure

8	Therapeutics 01/2021 - 06/2002
2	Lasers (Laser) 01/2017 - 02/2005
1	Electrodes (Electrode) 01/2021
1	Intraventricular Infusions 01/2019
1	Topical Administration 01/2018
1	Intraperitoneal Injections 11/2016